Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
15
SPRC Quote, Financials, Valuation and Earnings
Last price:
$1.35
Seasonality move
:
-20.72%
Day range:
$1.35 - $1.51
52-week range:
$1.30 - $37.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.77x
P/B ratio:
24.36x
Volume:
414.2K
Avg. volume:
2.6M
1-year change:
-84.79%
Market cap:
$4.5M
Revenue:
$1.3M
EPS (TTM):
-$4.87
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SPRC
SciSparc Ltd.
|
-- | -- | -- | -- | -- |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $2.50 |
|
CGEN
Compugen Ltd.
|
$1.5M | -$0.09 | 10.1% | -9.81% | $6.25 |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-- | -$6.08 | -- | -66.65% | $399.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SPRC
SciSparc Ltd.
|
$1.37 | -- | $4.5M | -- | $0.00 | 0% | 0.77x |
|
CANF
Can-Fite BioPharma Ltd.
|
$0.17 | $2.50 | $2.7M | -- | $0.00 | 0% | 0.96x |
|
CGEN
Compugen Ltd.
|
$1.47 | $6.25 | $137.5M | 55.83x | $0.00 | 0% | 19.64x |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
PHGE
BiomX, Inc.
|
$2.00 | $399.00 | $3.1M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SPRC
SciSparc Ltd.
|
-- | 2.811 | -- | 1.60x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.899 | -- | -- |
|
CGEN
Compugen Ltd.
|
6.3% | 2.845 | 2.14% | 4.24x |
|
NSRX
Nasus Pharma
|
-- | 0.000 | -- | -- |
|
PHGE
BiomX, Inc.
|
38.57% | 0.072 | 20.14% | 1.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SPRC
SciSparc Ltd.
|
-- | -- | -68.15% | -68.15% | -- | -- |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
SciSparc Ltd. vs. Competitors
-
Which has Higher Returns SPRC or CANF?
Can-Fite BioPharma Ltd. has a net margin of -- compared to SciSparc Ltd.'s net margin of --. SciSparc Ltd.'s return on equity of -68.15% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SPRCSciSparc Ltd.-- -- $8.7M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About SPRC or CANF?
SciSparc Ltd. has a consensus price target of --, signalling upside risk potential of 796981.89%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 1357.73%. Given that SciSparc Ltd. has higher upside potential than Can-Fite BioPharma Ltd., analysts believe SciSparc Ltd. is more attractive than Can-Fite BioPharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SPRCSciSparc Ltd.0 0 0 CANFCan-Fite BioPharma Ltd.1 1 0 -
Is SPRC or CANF More Risky?
SciSparc Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.756%.
-
Which is a Better Dividend Stock SPRC or CANF?
SciSparc Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SciSparc Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRC or CANF?
SciSparc Ltd. quarterly revenues are --, which are smaller than Can-Fite BioPharma Ltd. quarterly revenues of --. SciSparc Ltd.'s net income of -- is lower than Can-Fite BioPharma Ltd.'s net income of --. Notably, SciSparc Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SciSparc Ltd. is 0.77x versus 0.96x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRCSciSparc Ltd.0.77x -- -- -- CANFCan-Fite BioPharma Ltd.0.96x -- -- --
-
Which has Higher Returns SPRC or CGEN?
Compugen Ltd. has a net margin of -- compared to SciSparc Ltd.'s net margin of -369.06%. SciSparc Ltd.'s return on equity of -68.15% beat Compugen Ltd.'s return on equity of -51.8%.
Company Gross Margin Earnings Per Share Invested Capital SPRCSciSparc Ltd.-- -- $8.7M CGENCompugen Ltd.12.75% -$0.07 $46.8M -
What do Analysts Say About SPRC or CGEN?
SciSparc Ltd. has a consensus price target of --, signalling upside risk potential of 796981.89%. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 325.17%. Given that SciSparc Ltd. has higher upside potential than Compugen Ltd., analysts believe SciSparc Ltd. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SPRCSciSparc Ltd.0 0 0 CGENCompugen Ltd.4 0 0 -
Is SPRC or CGEN More Risky?
SciSparc Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.
-
Which is a Better Dividend Stock SPRC or CGEN?
SciSparc Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SciSparc Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRC or CGEN?
SciSparc Ltd. quarterly revenues are --, which are smaller than Compugen Ltd. quarterly revenues of $1.9M. SciSparc Ltd.'s net income of -- is lower than Compugen Ltd.'s net income of -$7M. Notably, SciSparc Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SciSparc Ltd. is 0.77x versus 19.64x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRCSciSparc Ltd.0.77x -- -- -- CGENCompugen Ltd.19.64x 55.83x $1.9M -$7M
-
Which has Higher Returns SPRC or NSRX?
Nasus Pharma has a net margin of -- compared to SciSparc Ltd.'s net margin of --. SciSparc Ltd.'s return on equity of -68.15% beat Nasus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SPRCSciSparc Ltd.-- -- $8.7M NSRXNasus Pharma-- -- -- -
What do Analysts Say About SPRC or NSRX?
SciSparc Ltd. has a consensus price target of --, signalling upside risk potential of 796981.89%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that SciSparc Ltd. has higher upside potential than Nasus Pharma, analysts believe SciSparc Ltd. is more attractive than Nasus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings SPRCSciSparc Ltd.0 0 0 NSRXNasus Pharma0 0 0 -
Is SPRC or NSRX More Risky?
SciSparc Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SPRC or NSRX?
SciSparc Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SciSparc Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRC or NSRX?
SciSparc Ltd. quarterly revenues are --, which are smaller than Nasus Pharma quarterly revenues of --. SciSparc Ltd.'s net income of -- is lower than Nasus Pharma's net income of --. Notably, SciSparc Ltd.'s price-to-earnings ratio is -- while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SciSparc Ltd. is 0.77x versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRCSciSparc Ltd.0.77x -- -- -- NSRXNasus Pharma-- -- -- --
-
Which has Higher Returns SPRC or PHGE?
BiomX, Inc. has a net margin of -- compared to SciSparc Ltd.'s net margin of --. SciSparc Ltd.'s return on equity of -68.15% beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital SPRCSciSparc Ltd.-- -- $8.7M PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About SPRC or PHGE?
SciSparc Ltd. has a consensus price target of --, signalling upside risk potential of 796981.89%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 8150%. Given that SciSparc Ltd. has higher upside potential than BiomX, Inc., analysts believe SciSparc Ltd. is more attractive than BiomX, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPRCSciSparc Ltd.0 0 0 PHGEBiomX, Inc.1 0 0 -
Is SPRC or PHGE More Risky?
SciSparc Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.
-
Which is a Better Dividend Stock SPRC or PHGE?
SciSparc Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SciSparc Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRC or PHGE?
SciSparc Ltd. quarterly revenues are --, which are smaller than BiomX, Inc. quarterly revenues of --. SciSparc Ltd.'s net income of -- is lower than BiomX, Inc.'s net income of -$9.2M. Notably, SciSparc Ltd.'s price-to-earnings ratio is -- while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SciSparc Ltd. is 0.77x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPRCSciSparc Ltd.0.77x -- -- -- PHGEBiomX, Inc.-- -- -- -$9.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
